Goldman Sachs assigned a Neutral rating and $20 price target to Edgewise Therapeutics (EWTX) after having previously covered the stock with an Early-Stage Biotech rating. While the firm sees blockbuster potential for the company’s programs across multiple indications including sevasemten in Becker muscular dystrophy, where there is no currently approved FDA therapy, and Duchenne muscular dystrophy, it also sees limited opportunities for the stock to re-rate over the next 12 months given expected clinical and regulatory updates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics downgraded to Neutral from Buy at Goldman Sachs
- JPMorgan cuts Edgewise target, remains from Analyst Focus List
- Edgewise Therapeutics Advances in Muscular Dystrophy Trials
- Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)